PATRICK ROSE: Open Payments
NPI 1811208341 · SAINT CLAIR, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,242 in 144 payments from 21 companies in 2025. Trend: 2023 $3,017 · 2024 $2,070 · 2025 $2,242
Food & beverage: $2,242
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $449 |
| AstraZeneca Pharmaceuticals LP | 7 | $239 |
| Novo Nordisk Inc | 16 | $209 |
| Lilly USA, LLC | 8 | $178 |
| Amgen Inc. | 19 | $161 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $158 |
| PFIZER INC. | 16 | $147 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $104 |
| SANOFI-AVENTIS U.S. LLC | 3 | $93 |
| Otsuka America Pharmaceutical, Inc. | 4 | $93 |
Products named: VRAYLAR, MOUNJARO, FARXIGA, XIFAXAN, UBRELVY, OTEZLA, CAPLYTA, NURTEC ODT.
Industry payments across MO — which companies pay providers there.
